Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 129, Issue -, Pages 319-329Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2017.12.001
Keywords
Tissue engineering; Regenerative medicine; Immunity; Immunosuppression; Immunodeficient; Infection
Categories
Funding
- U.S. Army, Navy, NIH, U.S. Air Force, VA and Health Affairs [W81XWH-14-2-0004]
- U.S. Army Medical Research Acquisition Activity, Fort Detrick MD
- John S. Dunn Foundation
- National Institutes of Health [R01 AR068073]
Ask authors/readers for more resources
As regenerative medicine matures as a field, more promising technologies are being translated from the benchtop to the clinic. However, many of these strategies are designed with otherwise healthy hosts in mind and validated in animal models without other co-morbidities. In reality, many of the patient populations benefiting from drug delivery and tissue engineering-based devices to enhance wound healing also have significant underlying immunodeficiency. Specifically, patients suffering from diabetes, malignancy, human immunodeficiency virus, post organ transplantation, and other compromised states have significant pleotropic immune defects that affect wound healing. In this work, we review the role of different immune cells in the regenerative process, highlight the effect of several common immunocompromised states on wound healing, and discuss different drug delivery strategies for overcoming immunodeficiencies. (C) 2017 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available